SOMERSET, N.J., July 6, 2010 (GLOBE NEWSWIRE) -- Tamir Biotechnology, Inc. (formerly known as Alfacell Corporation) (OTCBB:ACEL) today announced that it has selected Pharmatech Oncology, Inc. as the Clinical Research Organization (CRO) to run its upcoming Phase II trial of RANPIRNASE (ONCONASE®) in combination with platinum doublet chemotherapy for patients with advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).
